Share
.webp)
.webp)
.webp)
.webp)
Adrian Quartel
Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical needs, has appointed Adrian Quartel, M.D., FFPM, as Chief Medical Officer.
Dr. Quartel brings more than 25 years of international pharmaceutical industry experience across clinical development, pharmacovigilance, and medical affairs. He has a strong track record in advancing and launching enzyme replacement therapies for rare diseases.
Dr. Quartel joins Spruce from Zevra Therapeutics, where he served as Chief Medical Officer and helped lead clinical development, medical affairs, and regulatory strategy for the company’s rare disease portfolio. Previously, he served as Chief Medical Officer of Acer Therapeutics and Adamas Pharmaceuticals.
Earlier, as Group Vice President of Global Medical Affairs at BioMarin Pharmaceutical, Dr. Quartel led the launch of six treatments for rare diseases and genetic disorders, including the enzyme replacement therapies NAGLAZYME®, VIMIZIM®, and Brineura®. Brineura is used to treat a rare pediatric neurodegenerative disorder.
Before joining BioMarin, Dr. Quartel held senior medical leadership and clinical development roles at Astellas, Chiltern, and ICON Clinical Research. He earned his M.D. from Erasmus University Medical School in Rotterdam and completed postgraduate specialization in pharmaceutical medicine through the Faculty of Pharmaceutical Medicine. He is board certified in pharmaceutical medicine by the General Medical Council (GMC) in the United Kingdom.
